354 Studies Now Enrolling
Menu
Search
Displaying 1 - 6 of 6
Condition: Neurological Disorders / Brain Tumors
Investigator: Fabio Iwamoto, MD
Status: Currently Recruiting
The purpose of this study is to learn the effects of the investigational new drug, tirabrutinib, when given for the treatment of PCNSL. Investigational new drug means a drug that has not been approved as a marketed product (that is, available to be prescribed or sold) by the United States (US) Food and Drug Administration (FDA). Tirabrutinib acts by…
Condition: Cancer / Solid Tumors
Investigator: Nobuko Hijiya, MD
Status: Closed
The purpose of this study is to find out what dose of Tegavivint should be used with children and how well it works when given to patients between the ages of 12 months to 30 years of age with refractory or recurrent solid tumors, lymphomas, desmoid tumors, Ewing Sarcomas, osteosarcomas, liver tumors (HCC and hepatoblastoma),…
Condition: Cancer / Solid Tumors
Investigator: Nobuko Hijiya, MD
Status: Closed
The purpose of this study is to find the highest dose of CBL0137 that can be given safely to patients with solid tumors that have come back (relapsed) or does not respond to treatment (refractory) solid tumors, including the CNS tumors and lymphoma. CBL0137 will be given into a vein on Day 1 and Day 8 of a 21 day cycle for up…
Condition: Cancer / Solid Tumors
Investigator: Gary Schwartz, MD
Status: Closed
The primary purpose of this research study is to evaluate the safety, tolerability and maximum tolerated dose of BAY 1143572. Moreover, concentrations of BAY 1143572 as well as of biomarker proteins may provide information about the effects of BAY 1143572, will be determined in blood and tumor tissue.
Condition: Cancer / Solid Tumors
Investigator: Gary Schwartz, MD
Status: Closed
The purpose of this study is to find the highest dose and the best schedule of the study drug, DS-3032b, that can be given safely in subjects with advanced solid tumors and for subjects that did not respond or no longer respond to standard therapy. DS-3032b works against cancer by blocking the activity of a protein called MDM2. DS-3032b works against…
Condition: Neurological Disorders / Brain Tumors
Investigator: Fabio Iwamoto, MD
Status: Currently Recruiting
This study is being done to test the orally administered study drug, CA-4948 alone, in combination with ibrutinib, or ibrutinib alone in adult patients ages 18 and over diagnosed with relapsed or refractory (RR) Primary Central Nervous System Lymphoma (PCNSL). This study will take place at multiple centers globally. The study…
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website,
you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the
Columbia University Website Cookie Notice.
I AGREE